9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Study of ABBV-181 in Participants With Advanced Solid Tumors

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Study of ABBV-181 in Participants With Advanced Solid Tumors

A Study of ABBV-181 in Participants With Advanced Solid Tumors

Estimated reading time: < 1 min

Condition: Advanced Solid Tumors

Estimated Enrollment: 221

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Recommended Phase 2 Dose (RPTD) and schedule for ABBV-181 and venetoclax combination.,  Maximum tolerated dose (MTD) of ABBV-181,  Recommended Phase 2 Dose (RPTD) for ABBV-181, Time to Cmax (Tmax)

Interventions: Venetoclax, Rovalpituzumab Tesirine

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: September 25, 2021

Completion Date: December 27, 2021

Last  Posted Date: July 29, 2019

Location: Ucsd /Id# 157374, La Jolla, California, United States

Website Link: https://ClinicalTrials.gov/show/NCT03000257

Was this article helpful?
Dislike 0